Fig 5C shows Bcl-2 expression in the corresponding four comparison groups. The significant down-regulation of the Bcl-2 level in response to a combination therapy (Fig 5C) eventually leads to the apoptotic status and efficient tumor cell killing as well as prevention of CRCC (Fig 5A). Therefore, our phenomenological model is able to reproduce these responses from experimental data (Fig 5D) [10] in four cases. This evidence concerns the gene BCL2 and chromophobe renal cell carcinoma.